Lactate-induced PPP1R1B upregulation drives resistance to neoadjuvant immunotherapy in NSCLC via IRF3 dephosphorylation
Cancer Letters · 2026-12 · 663 · 218929
DOI: 10.1016/j.canlet.2026.218929 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-12. Verfasst von Ziyi Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of M…. Die Arbeit nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Major Science and Technology Projects of China, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
Neoadjuvant immunotherapy has improved clinical outcomes in resectable non-small cell lung cancer (NSCLC); however, a substantial proportion of patients fail to achieve durable responses, and the mechanisms underlying therapeutic resistance remain incompletely understood. Here, we identified protein phosphatase 1 regulatory inhibitor subunit 1B (PPP1R1B) as a metabolic driver of immunotherapy resistance in NSCLC through RNA sequencing of tumors with differential responses to neoadjuvant anti-PD-1 therapy. PPP1R1B was significantly upregulated in non-responders and correlated with poor prognosis in NSCLC patients. Mechanistically, PPP1R1B directly interacted with IRF3 through the Arg29 residue and promoted dephosphorylation of IRF3 at Ser396, thereby suppressing IRF3 activation and downstream interferon-β (IFN-β) signaling. PPP1R1B-mediated inhibition of IFN-β signaling reduced CD8+ T-cell infiltration and impaired antitumor immunity, ultimately conferring resistance to anti-PD-1 therapy in vivo. Blockade of IFN-β signaling abrogated the antitumor effects induced by PPP1R1B depletion, supporting an immune-dependent mechanism. Notably, tumors resistant to neoadjuvant immunotherapy exhibited impaired oxidative phosphorylation and excessive lactate accumulation. Lactate induced PPP1R1B expression through NF-κB-dependent transcriptional activation, linking metabolic reprogramming to innate immune suppression. Collectively, our findings identify a lactate/NF-κB/PPP1R1B/IRF3 signaling axis that drives immune evasion and resistance to neoadjuvant immunotherapy in NSCLC, and nominate PPP1R1B as a potential biomarker and therapeutic target for overcoming anti-PD-1 resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, Chi…
Förderung
- National Natural Science Foundation of China
- National Major Science and Technology Projects of China
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
Zitieren
APA
Jiang, Z., Yuan, J., Li, G., Wang, X., Zhao, J., Li, M., Zhang, Y., Liu, M., Jiao, Y., & Wang, X. (2026). Lactate-induced PPP1R1B upregulation drives resistance to neoadjuvant immunotherapy in NSCLC via IRF3 dephosphorylation. Cancer Letters, 663, 218929. https://doi.org/10.1016/j.canlet.2026.218929
Vancouver
Jiang Z, Yuan J, Li G, Wang X, Zhao J, Li M, et al. Lactate-induced PPP1R1B upregulation drives resistance to neoadjuvant immunotherapy in NSCLC via IRF3 dephosphorylation. Cancer Letters. 2026;663:218929. doi:10.1016/j.canlet.2026.218929
BibTeX
@article{Jiang2026,
author = {Jiang, Ziyi and Yuan, Junhu and Li, Guangyu and Wang, Xin and Zhao, Junyi and Li, Mo and Zhang, Ying and Liu, Mei and Jiao, Yuchen and Wang, Xiaobing},
title = {Lactate-induced PPP1R1B upregulation drives resistance to neoadjuvant immunotherapy in NSCLC via IRF3 dephosphorylation},
journal = {Cancer Letters},
year = {2026},
volume = {663},
pages = {218929},
doi = {10.1016/j.canlet.2026.218929}
}
EUVIMED